Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zand Quietussin herbal syrup, a "mild expectorant" for cold/flu/allergy, shipping in August.

This article was originally published in The Tan Sheet

Executive Summary

ZAND QUIETUSSIN HERBAL SYRUP "EASES COUGH, CONGESTION AND THROAT IRRITATION," the company claims in trade materials for the product. Slated to be shipped to natural food stores and mass merchandisers in August, Quietussin is a "soothing cough syrup" containing "loquat in a unique blend of Eastern and Western herbs," Zand states. With honey and vitamin C, Quietussin is an "excellent product for the cold, flu and allergy seasons," the company adds. A 4 oz. bottle will retail for about $9.99. Zand introduced Quietussin and a number of other new herbal products at the National Nutritional Foods Association Marketplace '97 conference in Las Vegas July 13-16.

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel